RZLT - READ THIS or miss an obvious 2-5x growth …

RZLT looks massively undervalued following a recent panic sell which now looks to be a foolish move by shareholders. RZLT just got obliterated after the Phase 3 sunRIZE data and in my view this looks far more like forced capitulation than a rational valuation of what is actually left. The stock dropped close to ninety percent in a straight line after headlines said the trial failed. Funds hit sell, algos followed, stops were triggered and liquidity disappeared. That kind of move almost never reflects calm analysis of the underlying data. It reflects panic. Here is what actually happened. (Chat GPT outiput FYi) Congenital HI: “Failed trial” but not a failed drug On paper, sunRIZE missed its primary and key secondary endpoints. Normally that kills a biotech. But what Rezolute showed was: • Drug did what it’s supposed to do biologically • Both 5 mg/kg and 10 mg/kg arms hit target drug levels • Biomarkers moved exactly as expected (insulin signalling was blocked) • Responses matched Phase 2, which had been positive So investors now believe: “The drug works — the trial design failed.” That’s very different from “the drug doesn’t work”. The killer was the massive placebo effect: • Kids were monitored 24/7 • Caregivers got alerts • Doctors intervened constantly This alone reduced hypoglycaemia events even in the placebo arm, wiping out statistical separation. That’s not unusual in rare paediatric glucose disorders — and the FDA knows it. ⸻ 2️⃣ The Open-Label Extension (OLE) is the real smoking gun This is what flipped sentiment: • All 59 patients chose to continue • 57 are still on drug • Some have been on it 18 months • Several children have stopped all other therapies and are on ersodetug alone That’s incredibly powerful in rare disease biotech. If the drug wasn’t working or was unsafe, parents would not keep their kids on it — especially for 18 months. Wall Street reads this as: “The blinded trial failed, but the real-world data is screaming efficacy.” ⸻ 3️⃣ Tumour HI data was quietly very strong This part got less attention, but it’s arguably the bigger value driver. In the EAP: • These patients are in hospital on IV glucose / TPN just to stay alive • 75% were able to completely come off IV glucose/TPN That’s huge: • It’s objective • It’s hospital-measured • And it’s exactly the endpoint in the ongoing Phase 3 upLIFT study The upLIFT trial needs: • 9 out of \~16 patients to hit ≥50% reduction in glucose infusion EAP data suggests they’re already on track. This is why the FDA allowed: • A single-arm Phase 3 • Based on Breakthrough Therapy Designation That almost never happens unless FDA already believes the drug works.